Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
More patients overall prefer FFNS than MFNS*
56% of patients overall preferred FFNS vs 32% preferring MFNS, p<0.001. 1
This once-daily, patient-preferred option may contribute to enhanced treatment outcomes in AR patients due to improved treatment adherence. 2
Overall, 5 patients (2%) reported AEs with FFNS and 13 patients (4%) with MFNS. Few common AEs were reported: rhinorrhoea, nasal discomfort, cough. No severe safety issues were identified during the study. 1
References
- Yanez A, Dimitroff A, Bremner P, et al. A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis. Allergy Rhinol 2016;7(4):e183–e192.
- Yonezaki M, Akiyama K, Karaki M, et al. Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis. Auris Nasus Larynx 2016;43(3):292–297.
Avamys is a registered trademark of the GlaxoSmithKline group of companies
